4.6 Article

Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model

Journal

FRONTIERS IN ONCOLOGY
Volume 10, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2020.01195

Keywords

immunotherapy; cancer models; computational immunology; triple negative breast cancer

Categories

Funding

  1. European Research Council (ERC) under the European Union [789256]
  2. European Research Council (ERC) [789256] Funding Source: European Research Council (ERC)

Ask authors/readers for more resources

Background:Tumor models are critical for our understanding of cancer and the development of cancer therapeutics. The 4T1 murine mammary cancer cell line is one of the most widely used breast cancer models. Here, we present an integrated map of the genome, transcriptome, and immunome of 4T1. Results:We found Trp53 (Tp53) and Pik3g to be mutated. Other frequently mutated genes in breast cancer, including Brca1 and Brca2, are not mutated. For cancer related genes, Nav3, Cenpf, Muc5Ac, Mpp7, Gas1, MageD2, Dusp1, Ros, Polr2a, Rragd, Ros1, and Hoxa9 are mutated. Markers for cell proliferation like Top2a, Birc5, and Mki67 are highly expressed, so are markers for metastasis like Msln, Ect2, and Plk1, which are known to be overexpressed in triple-negative breast cancer (TNBC). TNBC markers are, compared to a mammary gland control sample, lower (Esr1), comparably low (Erbb2), or not expressed at all (Pgr). We also found testis cancer antigen Pbk as well as colon/gastrointestinal cancer antigens Gpa33 and Epcam to be highly expressed. Major histocompatibility complex (MHC) class I is expressed, while MHC class II is not. We identified 505 single nucleotide variations (SNVs) and 20 insertions and deletions (indels). Neoantigens derived from 22 SNVs and one deletion elicited CD8(+)or CD4(+)T cell responses in IFN gamma-ELISpot assays. Twelve high-confidence fusion genes were observed. We did not observe significant downregulation of mismatch repair (MMR) genes or SNVs/indels impairing their function, providing evidence for 6-thioguanine resistance. Effects of the integration of the murine mammary tumor virus were observed at the genome and transcriptome level. Conclusions:4T1 cells share substantial molecular features with human TNBC. As 4T1 is a common model for metastatic tumors, our data supports the rational design of mode-of-action studies for pre-clinical evaluation of targeted immunotherapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Multidisciplinary Sciences

An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma

Ugur Sahin, Petra Oehm, Evelyna Derhovanessian, Robert A. Jabulowsky, Mathias Vormehr, Maike Gold, Daniel Maurus, Doreen Schwarck-Kokarakis, Andreas N. Kuhn, Tana Omokoko, Lena M. Kranz, Mustafa Diken, Sebastian Kreiter, Heinrich Haas, Sebastian Attig, Richard Rae, Katarina Cuk, Alexandra Kemmer-Brueck, Andrea Breitkreuz, Claudia Tolliver, Janina Caspar, Juliane Quinkhardt, Lisa Hebich, Malte Stein, Alexander Hohberger, Isabel Vogler, Inga Liebig, Stephanie Renken, Julian Sikorski, Melanie Leierer, Verena Mueller, Heidrun Mitzel-Rink, Matthias Miederer, Christoph Huber, Stephan Grabbe, Jochen Utikal, Andreas Pinter, Roland Kaufmann, Jessica C. Hassel, Carmen Loquai, Oezlem Tuereci

NATURE (2020)

Article Gastroenterology & Hepatology

Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in Mice

Bernd Heinrich, Zachary J. Brown, Laurence P. Diggs, Mathias Vormehr, Chi Ma, Varun Subramanyam, Umberto Rosato, Benjamin Ruf, Juliane S. Walz, John C. McVey, Simon Wabitsch, Qiong Fu, Su Jong Yu, Qianfei Zhang, Chunwei W. Lai, Ugur Sahin, Tim F. Greten

Summary: This study found that steatohepatitis reduces infiltration of CD4(+) T cells and effector memory cells in liver tumors, which decreases the efficacy of immunotherapeutic agents like M30 and aOX40 in inhibiting tumor growth. N-acetylcysteine can restore T-cell numbers in tumors and enhance the ability of M30 and aOX40 to slow tumor growth in mice.

GASTROENTEROLOGY (2021)

Correction Multidisciplinary Sciences

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses (vol 586, pg 594, 2020)

Ugur Sahin, Alexander Muik, Evelyna Derhovanessian, Isabel Vogler, Lena M. Kranz, Mathias Vormehr, Alina Baum, Kristen Pascal, Jasmin Quandt, Daniel Maurus, Sebastian Brachtendorf, Verena Lorks, Julian Sikorski, Rolf Hilker, Dirk Becker, Ann-Kathrin Eller, Jan Grutzner, Carsten Boesler, Corinna Rosenbaum, Marie-Cristine Kuhnle, Ulrich Luxemburger, Alexandra Kemmer-Bruck, David Langer, Martin Bexon, Stefanie Bolte, Katalin Kariko, Tania Palanche, Boris Fischer, Armin Schultz, Pei-Yong Shi, Camila Fontes-Garfias, John L. Perez, Kena A. Swanson, Jakob Loschko, Ingrid L. Scully, Mark Cutler, Warren Kalina, Christos A. Kyratsous, David Cooper, Philip R. Dormitzer, Kathrin U. Jansen, Ozlem Tureci

NATURE (2021)

Article Multidisciplinary Sciences

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Annette B. Vogel, Isis Kanevsky, Ye Che, Kena A. Swanson, Alexander Muik, Mathias Vormehr, Lena M. Kranz, Kerstin C. Walzer, Stephanie Hein, Alptekin Gueler, Jakob Loschko, Mohan S. Maddur, Ayuko Ota-Setlik, Kristin Tompkins, Journey Cole, Bonny G. Lui, Thomas Ziegenhals, Arianne Plaschke, David Eisel, Sarah C. Dany, Stephanie Fesser, Stephanie Erbar, Ferdia Bates, Diana Schneider, Bernadette Jesionek, Bianca Saenger, Ann-Kathrin Wallisch, Yvonne Feuchter, Hanna Junginger, Stefanie A. Krumm, Andre P. Heinen, Petra Adams-Quack, Julia Schlereth, Stefan Schille, Christoph Kroener, Ramon de la Caridad Guimil Garcia, Thomas Hiller, Leyla Fischer, Rani S. Sellers, Shambhunath Choudhary, Olga Gonzalez, Fulvia Vascotto, Matthew R. Gutman, Jane A. Fontenot, Shannan Hall-Ursone, Kathleen Brasky, Matthew C. Griffor, Seungil Han, Andreas A. H. Su, Joshua A. Lees, Nicole L. Nedoma, Ellene H. Mashalidis, Parag Sahasrabudhe, Charles Y. Tan, Danka Pavliakova, Guy Singh, Camila Fontes-Garfias, Michael Pride, Ingrid L. Scully, Tara Ciolino, Jennifer Obregon, Michal Gazi, Ricardo Carrion, Kendra J. Alfson, Warren Kalina, Deepak Kaushal, Pei-Yong Shi, Thorsten Klamp, Corinna Rosenbaum, Andreas N. Kuhn, Ozlem Tureci, Philip R. Dormitzer, Kathrin U. Jansen, Ugur Sahin

Summary: The two vaccine candidates, BNT162b1 and BNT162b2, developed contain modified messenger RNA encoding immunogens derived from the spike glycoprotein of SARS-CoV-2. They have shown promising immune responses in mice and rhesus macaques, with ongoing phase I trials in Germany and the USA and a global phase II/III trial for BNT162b2.

NATURE (2021)

Article Biochemical Research Methods

NeoFox: annotating neoantigen candidates with neoantigen features

Franziska Lang, Pablo Riesgo Ferreiro, Martin Loewer, Ugur Sahin, Barbara Schroers

Summary: The study focused on detecting and predicting true neoantigens, leading to the development of an easy-to-use tool called NeoFox for annotating neoantigen candidates with 16 features.

BIOINFORMATICS (2021)

Review Biochemistry & Molecular Biology

mRNA therapeutics in cancer immunotherapy

Jan D. Beck, Daniel Reidenbach, Nadja Salomon, Ugur Sahin, Ozlem Tureci, Mathias Vormehr, Lena M. Kranz

Summary: Synthetic mRNA serves as a versatile template for protein synthesis and has a wide range of pharmaceutical applications, including cancer immunotherapy. Strategies such as stimulating pattern recognition receptors and nucleoside modification enhance the effectiveness and safety of mRNA vaccines.

MOLECULAR CANCER (2021)

Article Biochemistry & Molecular Biology

Comprehensive Genomic and Transcriptomic Analysis of Three Synchronous Primary Tumours and a Recurrence from a Head and Neck Cancer Patient

Luisa Bresadola, David Weber, Christoph Ritzel, Martin Loewer, Valesca Bukur, Oezlem Akilli-Oeztuerk, Julia Becker, Hisham Mehanna, Barbara Schroers, Fulvia Vascotto, Ugur Sahin, Anthony Kong

Summary: This study analysed genomic and transcriptomic profiles of three synchronous primary malignancies and a recurrence, finding remarkable heterogeneity among the primary tumors. The origin of the recurrence was traced through shared mutation patterns, and the patient carried germline variants that may predispose to carcinogenesis, along with a history of alcohol and tobacco consumption. Immune cell infiltration analysis revealed an immunosuppressive environment in all samples.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Article Multidisciplinary Sciences

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Ugur Sahin, Alexander Muik, Isabel Vogler, Evelyna Derhovanessian, Lena M. Kranz, Mathias Vormehr, Jasmin Quandt, Nicole Bidmon, Alexander Ulges, Alina Baum, Kristen E. Pascal, Daniel Maurus, Sebastian Brachtendorf, Verena Loerks, Julian Sikorski, Peter Koch, Rolf Hilker, Dirk Becker, Ann-Kathrin Eller, Jan Gruetzner, Manuel Tonigold, Carsten Boesler, Corinna Rosenbaum, Ludwig Heesen, Marie-Cristine Kuhnle, Asaf Poran, Jesse Z. Dong, Ulrich Luxemburger, Alexandra Kemmer-Brueck, David Langer, Martin Bexon, Stefanie Bolte, Tania Palanche, Armin Schultz, Sybille Baumann, Azita J. Mahiny, Gabor Boros, Jonas Reinholz, Gabor T. Szabo, Katalin Kariko, Pei-Yong Shi, Camila Fontes-Garfias, John L. Perez, Mark Cutler, David Cooper, Christos A. Kyratsous, Philip R. Dormitzer, Kathrin U. Jansen, Oezlem Tuereci

Summary: The BNT162b2 vaccine shows 95% efficacy in preventing COVID-19 by boosting neutralizing antibody titres and activating specific T cell responses. The vaccine-induced immune response is broad and stable, lasting for a prolonged period, providing good coverage against various SARS-CoV-2 variants.

NATURE (2021)

Review Biotechnology & Applied Microbiology

Identification of neoantigens for individualized therapeutic cancer vaccines

Franziska Lang, Barbara Schroers, Martin Loewer, Oezlem Tuereci, Ugur Sahin

Summary: This Review discusses the use of tumor-specific neoantigens in anticancer vaccines and introduces the mechanisms of neoantigen T cell recognition, as well as computational approaches to predict which neoantigens might confer proficient antitumor immunity in patients. Individualized treatment approaches are required to harness the full potential of the unique cancer mutations in each patient. Computational algorithms and machine-learning tools can be used to identify mutations, prioritize T cell-recognized antigens, and design personalized vaccines for each patient.

NATURE REVIEWS DRUG DISCOVERY (2022)

Article Multidisciplinary Sciences

Large-scale analysis of SARS-CoV-2 spike-glycoprotein mutants demonstrates the need for continuous screening of virus isolates

Barbara Schrors, Pablo Riesgo-Ferreiro, Patrick Sorn, Ranganath Gudimella, Thomas Bukur, Thomas Rosler, Martin Lower, Ugur Sahin

Summary: Research has shown that SARS-CoV-2 spike protein exhibits mutations, with the majority being recurrent variants. While most spike protein mutants have low mutation rates, some variants may impact antibody binding or T-cell recognition. Additionally, high-confidence subclonal variants were identified in around 2.6% of NGS datasets, indicating potential co-infections with various strains and intra-host evolution.

PLOS ONE (2021)

Article Biotechnology & Applied Microbiology

Accurate detection of tumor-specific gene fusions reveals strongly immunogenic personal neo-antigens

David Weber, Jonas Ibn-Salem, Patrick Sorn, Martin Suchan, Christoph Holtstraeter, Urs Lahrmann, Isabel Vogler, Kathrin Schmoldt, Franziska Lang, Barbara Schroers, Martin Loewer, Ugur Sahin

Summary: EasyFuse is a machine learning computational pipeline that accurately and sensitively detects personal gene fusions from transcriptome data in cancer samples, and it has been proven in immunogenicity testing that personal gene fusions are important in personalized immunotherapy.

NATURE BIOTECHNOLOGY (2022)

Article Multidisciplinary Sciences

pH-degradable, bisphosphonate-loaded nanogels attenuate liver fibrosis by repolarization of M2-type macrophages

Leonard Kaps, Anne Huppertsberg, Niklas Choteschovsky, Adrian Klefenz, Feyza Durak, Babara Schroers, Mustafa Diken, Emma Eichler, Sebastian Rosigkeit, Sascha Schmitt, Christian Leps, Alicia Schulze, Friedrich Foerster, Ernesto Bockamp, Bruno G. De Geest, Kaloian Koynov, Hans-Joachim Raeder, Stefan Tenzer, Federico Marini, Detlef Schuppan, Lutz Nuhn

Summary: In this study, liver fibrosis progression was prevented by repolarizing M2-type macrophages towards a non-fibrotic phenotype using a pH-degradable nanogel carrier system. The nanogels efficiently delivered the drug alendronate to nonparenchymal cells of fibrotic livers, reprogramming profibrotic M2 into antifibrotic M1 macrophages and preventing liver fibrosis progression. This approach has potential implications for the treatment of diseases driven by M2-type macrophages, including cancer.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Article Oncology

Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+T-cell Responses in Glioblastoma

Jian Wang, Tobias Weiss, Marian C. Neidert, Nora C. Toussaint, Reza Naghavian, Carla Selles Moreno, Magdalena Foege, Paula Tomas Ojer, Gioele Medici, Ivan Jelcic, Daniel Schulz, Elisabeth Rushing, Susanne Dettwiler, Barbara Schrors, Joo Heon Shin, Ron McKay, Catherine J. Wu, Andreas Lutterotti, Mireia Sospedra, Holger Moch, Erich F. Greiner, Bernd Bodenmiller, Luca Regli, Michael Weller, Patrick Roth, Roland Martin

Summary: The study developed a strategy to design neopeptides with enhanced immunogenicity through single amino acid mutations. Vaccination with these peptides resulted in immune responses from CD8+ T cells and CD4+ T cells upon tumor recurrence.

CLINICAL CANCER RESEARCH (2022)

Article Virology

CoVigator-A Knowledge Base for Navigating SARS-CoV-2 Genomic Variants

Thomas Bukur, Pablo Riesgo-Ferreiro, Patrick Sorn, Ranganath Gudimella, Johannes Hausmann, Thomas Roesler, Martin Loewer, Barbara Schroers, Ugur Sahin

Summary: CoVigator is a tool for monitoring SARS-CoV-2 mutations, providing a knowledge base, variant calling, and an interactive dashboard. It can identify and track virus mutations, offering the largest dataset on SARS-CoV-2 intrahost mutations and is available for download.

VIRUSES-BASEL (2023)

Article Immunology

MC38 colorectal tumor cell lines from two different sources display substantial differences in transcriptome, mutanome and neoantigen expression

Barbara Schroers, Brett J. Hos, Ikra G. Yildiz, Martin Loewer, Franziska Lang, Christoph Holtstraeter, Julia Becker, Mathias Vormehr, Ugur Sahin, Ferry Ossendorp, Mustafa Diken

Summary: The MC38 cell line, commonly used for colorectal carcinoma studies, has two sub-cell lines (MC38-K and MC38-L) with distinct genomic and transcriptomic differences. CD8+ T cell recognition also varies between the two sub-cell lines. This highlights the importance of accurately selecting the appropriate sub-cell line for research.

FRONTIERS IN IMMUNOLOGY (2023)

No Data Available